Mostrando 2 resultados de: 2
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
ArticleAbstract: Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability ofPalabras claves:Autores:Alyamani M., Bishop A., Bunch D., Dreicer R., Garcia J., Li Z., Liu J., Richard J. Auchus, Sharifi N., Upadhyay S.K.Fuentes:scopusHSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer
ArticleAbstract: BACKGROUND. A common germline variant in HSD3B1(1245A>C) encodes for a hyperactive 3β-hydroxysteroidPalabras claves:Autores:Almassi N., Alyamani M., Berk M.P., Chien C., Emamekhoo H., Figg W.D., Garcia J., Grivas P.D., Hu B., Hwang T.H., Koshkin V.S., Mendiratta P., Park S., Peer C.J., Richard J. Auchus, Rini B., Sharifi N., Taylor J., Tyler A., Upadhyay S.K.Fuentes:scopus